Search Results

Lakewood-Amedex Inc. announced that Sumita Paul, MD, MPH, MBA has joined Lakewood-Amedex as Chief Medical Officer and Senior Vice President, Research and Development to lead its recently recruited scientific-clinical management team.

Lakewood-Amedex, Inc. announced today that it has commenced its second Phase 2 study using Bisphosphocin Nu-3 antimicrobial in treating patients with diabetic foot ulcers (DFU).

Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors.

Transparency Life Sciences (TLS) today announced a partnership with the Lakewood Amedex Inc. for crowdsourced design of a Phase 2a/b protocol to test a novel class of synthetic broad-spectrum antimicrobials and antifungals for the treatment of Chronic Diabetic Foot Ulcers (cDFU).

Lakewood-Amedex Inc. announced that the U.S. Patent and Trademark Office has issued a “Notice of Allowance” for two broad patent applications related to the Company’s broad-spectrum antimicrobial Nu-8 Bisphosphocin compound, titled “Antimicrobial Compounds, Compositions, and Uses Thereof.” The “Notice of Allowance” indicates that the USPTO is satisfied that the patent applications meet all USPTO requirements.

Mesa Laboratories, Inc. will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 as previously communicated.

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today it had entered into a collaboration agreement with Nassau based Foot and Ankle International (Bahamas) to conduct two Phase 2 cDFU clinical trial for its topically applied Nu-3 antimicrobial used to eliminate infection and promote wound healing in patients with chronic diabetic foot ulcers (cDFU).

Mesa Laboratories, Inc. will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 31, 2024.

Lakewood-Amedex today announced that it will be advancing a second Bisphosphocin drug candidate, Nu-8, into preclinical IND-enabling studies.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system